...
首页> 外文期刊>Biotechnology Progress >In vitro hepatic steatosis model based on gut-liver-on-a-chip
【24h】

In vitro hepatic steatosis model based on gut-liver-on-a-chip

机译:基于肠道肝脏芯片的体外肝脏脂肪变性模型

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatic steatosis, also known as fatty liver disease, occurs due to abnormal lipid accumulation in the liver. It has been known that gut absorption also plays an important role in the mechanism underlying hepatic steatosis. Conventional in vitro cell culture models have limitations in recapitulating the mechanisms of hepatic steatosis because it does not include the gut absorption process. Previously, we reported development of a microfluidic gut-liver chip that can recapitulate the gut absorption of fatty acids and subsequent lipid accumulation in liver cells. In this study, we performed a series of experiments to verify that our gut-liver chip reproduces various aspects of hepatic steatosis. The absorption of fatty acids was evaluated under various culture conditions. The anti-steatotic effect of turofexorate isopropyl (XL-335) and metformin was tested, and both drugs showed different action mechanisms. In addition, the oxidative stress induced by lipid absorption was evaluated. Our results demonstrate the potential of the gut-liver chip for use as a novel, physiologically realistic in vitro model to study fatty liver disease.
机译:由于肝脏中的异常脂质积累,肝脏脂肪变性也被称为脂肪肝疾病。众所周知,肠道吸收也在肝脏脂肪变性的机制中起重要作用。常规体外细胞培养模型具有局限性地重新承载肝脏脂肪变性的机制,因为它不包括肠道吸收过程。以前,我们报道了一种显微流体肠道肝脏的开发,可以重新携带脂肪酸的肠道吸收和肝细胞中的脂质积累。在这项研究中,我们进行了一系列实验,以验证我们的肠肝芯片再现肝脏脂肪变性的各个方面。在各种培养条件下评价脂肪酸的吸收。测试强甲酸异丙基(XL-335)和二甲双胍的抗真实效果,两种药物显示出不同的作用机制。此外,评价脂质吸收诱导的氧化应激。我们的结果表明,肠肝芯片用作新的生理学上的体外模型的潜力,以研究脂肪肝疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号